Get the Stockscreener App
2.57
4.81%
-0.13
After Hours:
2.51
-0.06
-2.33%
Leap Therapeutics Inc stock is traded at $2.57, with a volume of 143.34K.
It is down -4.81% in the last 24 hours and down -11.38% over the past month.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
See More
Previous Close:
$2.70
Open:
$2.73
24h Volume:
143.34K
Relative Volume:
1.20
Market Cap:
$100.25M
Revenue:
$1.50M
Net Income/Loss:
$-81.41M
P/E Ratio:
-0.3948
EPS:
-6.51
Net Cash Flow:
$-43.75M
1W Performance:
-5.17%
1M Performance:
-11.38%
6M Performance:
-3.38%
1Y Performance:
+86.23%
1-Day Range:
$2.47
$2.815
1-Week Range:
$2.47
$2.815
52-Week Range:
$1.235
$5.00
Leap Therapeutics Inc Stock (LPTX) Company Profile
Name
Leap Therapeutics Inc
Sector
Industry
Phone
617 252 4343
Address
47 THORNDIKE STREET, CAMBRIDGE, MA
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-21 | Initiated | Mizuho | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Nov-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-13-19 | Resumed | Raymond James | Outperform |
| Mar-07-17 | Initiated | Ladenburg Thalmann | Buy |
View All
Leap Therapeutics Inc Stock (LPTX) Latest News
LPTXLeap Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients - StockTitan
Venous Leg Ulcers Treatment Market Growth, Size, Research Report and Forecast (2024-2034) - Talented India
Leap Therapeutics (NASDAQ:LPTX) Share Price Passes Below 50 Day Moving Average of $2.58 - MarketBeat
Biliary Tract Cancer Pipeline Analysis 2024: FDA Approvals - openPR
TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail
Simplify Asset Management Inc. Has $1.24 Million Stock Position in Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat
Simplify Asset Management Inc. Buys 255,293 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - Defense World
Meiji Yasuda Asset Management Co Ltd. Has $1.22 Million Stock Position in Hilton Worldwide Holdings Inc. (NYSE:HLT) - Defense World
Commonwealth Equity Services LLC Boosts Position in AllianzIM U.S. Large Cap Buffer10 Sep ETF (NYSEARCA:SEPT) - Defense World
Newmark Security (LON:NWT) Stock Price Crosses Above Two Hundred Day Moving Average of $91.75 - Defense World
How Analyst Ratings Affect Leap Therapeutics Inc Inc. (LPTX) Price Performance - The InvestChronicle
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story - Simply Wall St
Eli Lilly partners with AI-focused Genetic Leap to develop RNA-based drugs - Yahoo Finance
Vera Therapeutics (NASDAQ:VERA) vs. Pivotal Therapeutics (OTCMKTS:PVTTF) Financial Analysis - Defense World
Global Gastric Cancer Diagnostics Market is Expected to Expand at a CAGR of ~7% by 2030 | DelveInsight - PR Newswire UK
ORKA Stock Price and Chart — NASDAQ:ORKA - TradingView
Lululemon Athletica (NASDAQ:LULU) Price Target Lowered to $326.00 at Morgan Stanley - Defense World
Farther Finance Advisors LLC Has $1.20 Million Stake in Paychex, Inc. (NASDAQ:PAYX) - Defense World
Laramide Resources Ltd. (TSE:LAM) Director Buys C$10,200.00 in Stock - Defense World
Rothschild Investment LLC Buys Shares of 8,904 Capital Group Growth ETF (NYSEARCA:CGGR) - Defense World
Picton Mahoney Asset Management Takes $71,000 Position in American Woodmark Co. (NASDAQ:AMWD) - Defense World
Rothschild Investment LLC Makes New Investment in iShares Core MSCI Europe ETF (NYSEARCA:IEUR) - Defense World
Farther Finance Advisors LLC Has $1.36 Million Stake in McKesson Co. (NYSE:MCK) - Defense World
Intel Co. (NASDAQ:INTC) Shares Purchased by Farther Finance Advisors LLC - Defense World
Rothschild Investment LLC Takes Position in BlackRock MuniHoldings Quality Fund II, Inc. (NYSE:MUE) - Defense World
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Trims Stock Holdings in Universal Health Services, Inc. (NYSE:UHS) - Defense World
Allspring Global Investments Holdings LLC Sells 103,605 Shares of Wabash National Co. (NYSE:WNC) - Defense World
Leap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Update - MarketBeat
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 - GlobeNewswire
Atossa and Quantum Leap dose first subject in breast cancer therapy trial - Yahoo Finance
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - ForexTV.com
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - Yahoo Finance
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - StockTitan
Vanguard Group Inc. Buys 457,904 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat
AstraZeneca (LON:AZN) Stock Price Crosses Above 200-Day Moving Average of $11,535.34 - Defense World
Vanguard Group Inc. Acquires 156,044 Shares of Priority Technology Holdings, Inc. (NASDAQ:PRTH) - Defense World
Leap Therapeutics, Inc. (NASDAQ:LPTX) Sees Large Decline in Short Interest - MarketBeat
Leap Therapeutics, Inc. (NASDAQ:LPTX) Sees Large Decline in Short Interest - Defense World
Analysts Issue Forecasts for Leap Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:LPTX) - MarketBeat
Q3 2024 EPS Estimates for MiNK Therapeutics, Inc. (NASDAQ:INKT) Boosted by Analyst - Defense World
HLS Therapeutics Inc. (TSE:HLS) to Post Q3 2024 Earnings of ($0.19) Per Share, Stifel Canada Forecasts - Defense World
Leap Therapeutics (NASDAQ:LPTX) Given Buy Rating at HC Wainwright - MarketBeat
Leap Therapeutics’ (LPTX) Buy Rating Reaffirmed at HC Wainwright - Defense World
IonQ, Inc. (IONQ): A Quantum Leap in Computer Hardware with Promising Growth Potential - Yahoo Finance
LPTX Stock Earnings: Leap Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Leap Therapeutics Reports Second Quarter 2024 Financial Results - citybiz
Orphan Drugs and Rare Diseases Conference (Boston, MA, United StatesOctober 17-18, 2024)Navigating Orphan Drugs & Rare Diseases from Regulation to Detection & Precision TreatmentsResearchAndMarkets.com - Manchestertimes
Leap Therapeutics Reports Second Quarter 2024 Financial Results - PR Newswire
Venous Leg Ulcers Treatment Industry Size, Innovations Driving Industry Evolution (2024-2035) - அக்னி செய்திகள்
Travere Therapeutics (NASDAQ:TVTX) PT Raised to $14.00 at Barclays - Defense World
Leap Therapeutics Inc Stock (LPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):